RU2563193C2 - Комбинации ингибитора pi3k и ингибитора мек - Google Patents

Комбинации ингибитора pi3k и ингибитора мек Download PDF

Info

Publication number
RU2563193C2
RU2563193C2 RU2012118974/15A RU2012118974A RU2563193C2 RU 2563193 C2 RU2563193 C2 RU 2563193C2 RU 2012118974/15 A RU2012118974/15 A RU 2012118974/15A RU 2012118974 A RU2012118974 A RU 2012118974A RU 2563193 C2 RU2563193 C2 RU 2563193C2
Authority
RU
Russia
Prior art keywords
gdc
compound
patient
combination
present
Prior art date
Application number
RU2012118974/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012118974A (ru
Inventor
БЕЛВИН Маршия
Т. ЧАНЬ Айрис
ФРИДМАН Лори
П. ХЁФЛИХ Клаус
ПРЕСКОТТ Джон
УОЛЛИН Джеффри
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2563193(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2012118974A publication Critical patent/RU2012118974A/ru
Application granted granted Critical
Publication of RU2563193C2 publication Critical patent/RU2563193C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RU2012118974/15A 2009-10-12 2010-10-11 Комбинации ингибитора pi3k и ингибитора мек RU2563193C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
US61/250,852 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Publications (2)

Publication Number Publication Date
RU2012118974A RU2012118974A (ru) 2013-11-20
RU2563193C2 true RU2563193C2 (ru) 2015-09-20

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012118974/15A RU2563193C2 (ru) 2009-10-12 2010-10-11 Комбинации ингибитора pi3k и ингибитора мек

Country Status (24)

Country Link
US (1) US20110086837A1 (enExample)
EP (1) EP2488178B1 (enExample)
JP (2) JP2013507415A (enExample)
KR (1) KR101489045B1 (enExample)
CN (1) CN102740851B (enExample)
AR (1) AR078588A1 (enExample)
AU (1) AU2010314287A1 (enExample)
BR (1) BR112012008483A2 (enExample)
CA (1) CA2776944A1 (enExample)
CL (1) CL2012000913A1 (enExample)
CO (1) CO6531463A2 (enExample)
CR (1) CR20120173A (enExample)
EC (1) ECSP12011865A (enExample)
ES (1) ES2609767T3 (enExample)
IL (1) IL219105A0 (enExample)
MA (1) MA33974B1 (enExample)
MX (1) MX345155B (enExample)
NZ (1) NZ599939A (enExample)
PE (1) PE20121816A1 (enExample)
PH (1) PH12012500709A1 (enExample)
RU (1) RU2563193C2 (enExample)
TW (1) TWI428336B (enExample)
WO (1) WO2011054620A1 (enExample)
ZA (1) ZA201202618B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000440A (es) 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CA2830822C (en) 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN103957902A (zh) 2011-10-13 2014-07-30 基因泰克公司 药理学诱导的胃酸过少的治疗
EP2776051A4 (en) * 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
PE20142020A1 (es) * 2012-04-06 2014-12-24 Sanofi Sa Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
JP6093757B2 (ja) * 2012-04-19 2017-03-08 国立大学法人九州大学 医薬組成物
US9107926B2 (en) 2012-06-08 2015-08-18 Genentech, Inc. Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
US9463251B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
RS59113B1 (sr) * 2012-08-17 2019-09-30 Hoffmann La Roche Kombinovane terapije za melanom koje uključuju davanje kobimetiniba i vemurafiniba
SG11201507477XA (en) * 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
ES3014591T3 (en) 2018-09-11 2025-04-23 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
WO2007129161A2 (en) * 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
US20090156576A1 (en) * 2005-10-07 2009-06-18 Exelixis Inc. Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
WO1995026956A1 (en) * 1994-04-01 1995-10-12 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
EE05450B1 (et) * 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) * 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AU2007329352B2 (en) * 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20090156576A1 (en) * 2005-10-07 2009-06-18 Exelixis Inc. Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
WO2007129161A2 (en) * 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Харкевич Д.А. Фармакология: Учебник. " 9-е изд., доп. и испр. " М.: ГЭОТАР-Медиа, 2006. " 736 с. Olga K. Mirzoeva et al / Basal Subtype and (MAPK)/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition / Cancer Res / January 2009, Vol.69, N2, pages 565-572 *

Also Published As

Publication number Publication date
CO6531463A2 (es) 2012-09-28
US20110086837A1 (en) 2011-04-14
CR20120173A (es) 2012-07-04
WO2011054620A1 (en) 2011-05-12
HK1175125A1 (en) 2013-06-28
EP2488178A1 (en) 2012-08-22
PE20121816A1 (es) 2013-01-02
AU2010314287A1 (en) 2012-05-03
JP2015038110A (ja) 2015-02-26
RU2012118974A (ru) 2013-11-20
NZ599939A (en) 2014-02-28
IL219105A0 (en) 2012-06-28
CL2012000913A1 (es) 2012-09-14
CN102740851B (zh) 2013-12-18
ES2609767T3 (es) 2017-04-24
PH12012500709A1 (en) 2012-10-29
KR101489045B1 (ko) 2015-02-02
JP2013507415A (ja) 2013-03-04
AU2010314287A2 (en) 2012-07-12
TWI428336B (zh) 2014-03-01
JP5745678B2 (ja) 2015-07-08
EP2488178B1 (en) 2016-11-16
MX345155B (es) 2017-01-18
AR078588A1 (es) 2011-11-16
BR112012008483A2 (pt) 2019-09-24
ZA201202618B (en) 2014-10-29
ECSP12011865A (es) 2012-06-29
MX2012004286A (es) 2012-05-22
CN102740851A (zh) 2012-10-17
CA2776944A1 (en) 2011-05-12
MA33974B1 (fr) 2013-02-01
TW201118082A (en) 2011-06-01
KR20120064132A (ko) 2012-06-18

Similar Documents

Publication Publication Date Title
RU2563193C2 (ru) Комбинации ингибитора pi3k и ингибитора мек
Zhao et al. The clinical development of MEK inhibitors
EP2205242B1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20200246338A1 (en) Combination therapy
JP2024526145A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤を含む組合せ医薬及び癌の治療のためのその使用
CN113840606A (zh) 给药kras抑制剂治疗癌症
JP2021046430A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
JP2020079243A (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
JP2016529285A (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
EP4554581A1 (en) Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors
CN115776889A (zh) 用于治疗非小细胞肺癌的egfr tki
KR20250121542A (ko) 진행성 고형 종양의 치료 방법
HK1175125B (en) Combinations of a pi3k inhibitor and a mek inhibitor
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
Teicher et al. Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models
JP2025530296A (ja) 転移性癌を治療するためのｐｌｋ１阻害剤と抗血管新生剤の併用
CN117043159A (zh) Kras突变型癌症的治疗
HK40087830A (zh) 用於癌症治疗的贝伐非尼
CN119013026A (zh) 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法
Haddley Linifanib
HK1145287B (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171012